title: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.
abstract: These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.
authors.affiliation: Division of Clinical Neurosciences, University of Southampton, Southampton, UK. dsb1@soton.ac.uk
authors.forename: David S
authors.initials: DS
authors.lastname: Baldwin
authors.forename: Ian M
authors.initials: IM
authors.lastname: Anderson
authors.forename: David J
authors.initials: DJ
authors.lastname: Nutt
authors.forename: Borwin
authors.initials: B
authors.lastname: Bandelow
authors.forename: A
authors.initials: A
authors.lastname: Bond
authors.forename: Jonathan R T
authors.initials: JR
authors.lastname: Davidson
authors.forename: J A
authors.initials: JA
authors.lastname: den Boer
authors.forename: Naomi A
authors.initials: NA
authors.lastname: Fineberg
authors.forename: Martin
authors.initials: M
authors.lastname: Knapp
authors.forename: J
authors.initials: J
authors.lastname: Scott
authors.forename: H-U
authors.initials: HU
authors.lastname: Wittchen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D001521:Behavior Therapy; D001942:Breast Feeding; D002675:Child, Preschool; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D011619:Psychotropic Drugs